Concepedia

Brenda J Curry

BJ

Statistics

Publications

7

Citations

1.8K

H-Index

7

Active since

1990

Affiliations

AstraZeneca (United Kingdom)(Current)

Brenda J Curry is an author at AstraZeneca (United Kingdom) specializing in tyrosine kinase inhibitors, growth factor signaling, and oncology.

Publications per year

1990–2003

7

Publications

7

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge, Donald Ogilvie, Michael Dukes et al. · PubMed · 2002 · 802 citations

, , +15

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Andrew Barker, Keith H. Gibson, Walter Grundy et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 563 citations · Full text

, , +9

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Stephen R. Wedge, DJ Ogilvie, Michael Dukes et al. · PubMed · 2000 · 194 citations

, , +16

ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT

J.R. Woodburn, Andrew Barker, Keith H. Gibson et al. · Journal of Immunotherapy · 1997 · 66 citations

, , +7

Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines

Keith H. Gibson, Walter Grundy, Andrew A. Godfrey et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 55 citations

, , +14

1–5 of 7